ClinicalTrials.gg
Active, not recruitingNCT05253651MOUNTAINEER-03Updated Nov 16, 2026

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

A Phase 3 interventional study of tucatinib and trastuzumab in Colorectal Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Active, not recruiting at 319 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment

Updated Nov 16, 2026Now Active, not recruitingNo longer in Austria+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing trastuzumab in Colorectal Neoplasms — 3 open to participants now, 5 under way, 2 of them phase 3. Trastuzumab · Colorectal Neoplasms.

Planned enrollment
3rd of 15
400 · median 35
Started
2022
with 2 others
Phase 3
Only one
of the 15
Registered
11th of 15
by date
Lead sponsor
1 of 15
Seagen, a wholly owned subsidiary of Pfizer

Among the 15 studies testing trastuzumab in Colorectal Neoplasms, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2022, is the only one in phase 3, and was the 11th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 15 studies testing trastuzumab in Colorectal Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing trastuzumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.

Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable).

Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either:

  • mFOLFOX6 alone,
  • mFOLFOX6 with bevacizumab, or
  • mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
03

Conditions studied

  • Colorectal Neoplasms

Keywords

  • Colorectal Cancer
  • CRC
  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • and/or cytologically confirmed adenocarcinoma of the colon or rectum which is locally advanced unresectable or
  • Able to provide the most recently available formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks (or freshly sectioned slides) obtained prior to treatment initiation to a central laboratory

    • If is not available, a newly-obtained baseline biopsy of an accessible tumor lesion is required within 35 days prior to start of study treatment
  • + disease as determined by a tissue based assay performed at a central laboratory.
  • Participant has rat sarcoma viral oncogene homolog wild-type (RAS WT) disease as determined by local or central testing. For central RAS analysis, tissue sample must be analyzed within 1 year of biopsy date.
  • Radiographically per v1.1 with:

    • At least one site of disease that is measurable and that has not been previously irradiated, or
    • If the participant has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation
  • (ECOG) Performance Status of 0 or 1
  • CNS Inclusion - based on contrast brain magnetic resonance imaging, participants may have any of the following:

    • No evidence of
    • Previously treated brain metastases which are asymptomatic

Exclusion criteria

Exclusion Criteria:

  • Prior systemic anticancer therapy for colorectal cancer (CRC) in the locally advanced unresectable or setting; note that participants may have received a maximum of 2 doses of mFOLFOX6 in the locally advanced/unresectable or metastatic setting prior to randomization.

    • Note: May have received chemotherapy for CRC in the setting if it was completed >6 months prior to enrollment
  • Radiation therapy within 14 days prior to enrollment (or within 7 days in the setting of stereotactic radiosurgery)
  • Previous treatment with anti- therapy
  • Ongoing Grade 3 or higher neuropathy
  • Active or untreated gastrointestinal (GI) perforation at the time of screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Tucatinib Arm

    Tucatinib + trastuzumab + mFOLFOX6

    Drug: tucatinib · Drug: trastuzumab · Drug: oxaliplatin · Drug: leucovorin · Drug: levoleucovorin · Drug: fluorouracil

  • Active comparator
    Standard of Care Arm

    Either (1) mFOLFOX6, (2) mFOLFOX6 and bevacizumab, or (3) mFOLFOX6 and cetuximab

    Drug: bevacizumab · Drug: cetuximab · Drug: oxaliplatin · Drug: leucovorin · Drug: levoleucovorin · Drug: fluorouracil

Interventions

  • 300mg given by mouth (orally) twice daily

    Also known as: TUKYSA, ONT-380, ARRY-380, PF-07265792

  • 8mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 day 1, followed by 6mg/kg given by IV every 3 weeks thereafter.

    Also known as: Herceptin

  • 5mg/kg given by IV every 2 weeks

    Also known as: Avastin

  • 400mg/m2 loading dose will be given by IV on Cycle 1 day 1, followed by 250mg/m2 given by IV weekly

    Also known as: Erbitux

  • 85mg/m2 given by IV every 2 weeks. Component of mFOLFOX6.

  • 400mg/ m2 given by IV every 2 weeks. Component of mFOLFOX6.

  • 200mg/ m2 given by IV every 2 weeks. May be given in place of leucovorin. Component of mFOLFOX6.

  • 400mg/m2 given by IV bolus then 2400mg/m2 given by continuous IV infusion (over 46-48 hours) every 2 weeks. Component of mFOLFOX6.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR)

    The time from the date of randomization to the BICR assessment of disease progression according to RECIST v1.1 or death from any cause

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Overall survival (OS)

    The time from randomization to death from any cause

    Time frame: Up to approximately 6 years

  2. Confirmed objective response rate (cORR) per RECIST v1.1 by BICR

    The proportion of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1, as assessed by BICR

    Time frame: Up to approximately 3 years

  3. PFS per RECIST v1.1 by investigator assessment

    The time from the date of randomization to the investigator assessment of disease progression according to RECIST v1.1 or death from any cause

    Time frame: Up to approximately 3 years

  4. cORR per RECIST v1.1 by investigator assessment

    The proportion of participants with confirmed CR or PR according to RECIST v1.1, as assessed by investigators

    Time frame: Up to approximately 3 years

  5. Duration of response (DOR) per RECIST v1.1 by BICR

    The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of disease progression per RECIST v1.1 or death from any cause

    Time frame: Up to approximately 3 years

  6. DOR per RECIST v1.1 by investigator assessment

    The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of disease progression per RECIST v1.1 or death from any cause

    Time frame: Up to approximately 3 years

  7. Time to second progression or death (PFS2)

    The time from randomization to disease progression on the next-line of therapy, or death from any cause

    Time frame: Up to approximately 3 years

  8. Incidence of adverse events (AEs)

    Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Through 30 days after the last study treatment; approximately 1 year

  9. Incidence of dose alterations

    Time frame: Through 30 days after the last study treatment; approximately 1 year

  10. Trough concentration (Ctrough)

    PK parameter

    Time frame: Approximately 4 months

  11. Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQC30) score

    Change from baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) scores. Scale scores range from 0-100. For functioning and global health status/quality of life (QoL) scales, higher scores indicate better functioning or global health status/quality of life (QoL). For symptom scales, higher scores indicate greater symptom burden.

    Time frame: Through 30-37 days after the last study treatment; approximately 1 year

  12. Time to meaningful change in EORTC QLQ30 score

    The time from baseline to the first onset of a ≥10-point changes in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) scores. Scale scores range from 0-100. For functioning and global health status/QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden.

    Time frame: Through 30-37 days after the last study treatment; approximately 1 year

07

Study locations

319 sites

Showing the first 100 of 319 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Strickler JH, Bekaii-Saab T, Cercek A, Heinemann V, Nakamura Y, Raghav K, Siena S, Tabernero J, Van Cutsem E, Yoshino T, Ramos J, Guan X, Andre T. MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future Oncol. 2025 Feb;21(3):303-311. doi: 10.1080/14796694.2024.2441101. Epub 2024 Dec 26. PubMed 39723627 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Dec 2027, 62 months after the start.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's planned 62 months is above that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2022
First posted
Feb 24, 2022
StartActual
Oct 24, 2022
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jul 3, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 16, 2026
Sites
17 sites added, 64 sites removed; no longer in Austria
Show 17 added (14 United States, 2 Italy, 1 United Kingdom)
  • Mount Sinai Braman Comprehensive Cancer Center · Miami Beach, United States
  • Minnesota Oncology & Ridgeview Cancer & Infusion Center · Waconia, United States
  • Memorial Sloan Kettering Cancer Center - Main Campus · New York, United States
  • Texas Oncology - DFW · Arlington, United States
  • Texas Oncology - DFW · Arlington, United States
  • Texas Oncology - DFW · Bedford, United States
  • Texas Oncology - DFW · Dallas, United States
  • Texas Oncology - DFW · Dallas, United States
  • Texas Oncology - DFW · Dallas, United States
  • Texas Oncology - DFW · Dallas, United States
  • Texas Oncology - DFW · Fort Worth, United States
  • Texas Oncology - DFW · Grapevine, United States
  • Texas Oncology - DFW · Plano, United States
  • Texas Oncology - DFW · Plano, United States
  • IRCCS Azienda Ospedaliera Metropolitana (IRCCS AOM) · Genova, Italy
  • Azienda Ospedaliera Universitaria Luigi Vanvitelli · Naples, Italy
  • Cambridge University Hospitals NHS Foundation Trust, Oncology Centre · Cambridge, United Kingdom
Show 64 removed
  • University of Southern California · Los Angeles, United States
  • Mount Sinai Comprehensive Cancer Center · Miami Beach, United States
  • Minnesota Oncology Hematology, PA · Fridley, United States
  • Minnesota Oncology Hematology, PA · Minneapolis, United States
  • Memorial Solan Kettering Cancer Center- Main Campus · New York, United States
  • Providence Cancer Institute Newberg Clinic · Newberg, United States
  • Providence Cancer Institute Willamette Falls Clinic · Oregon City, United States
  • Providence Portland Medical Center-Westside · Portland, United States
  • Providence St. Vincent Medical Center- Investigational Drug Services · Portland, United States
  • UPMC Hillman Cancer Center - Washington · Washington, United States
  • US Oncology Investigational Product Center (IPC) · Irving, United States
  • US Oncology Investigational Products Center (IPC) · Irving, United States
  • Providence Regional Cancer Partnership · Everett, United States
  • Providence Regional Medical Center Everett · Everett, United States
  • Princess Alexandra Hospital · Woolloongabba, Australia
  • Klinikum Wels-Grieskirchen GmbH Austria · Wels, Austria
  • Uniklinikum Salzburg, Landeskrankenhaus · Salzburg, Austria
  • AKH - Medizinische Universitat Wien · Vienna, Austria
  • Klinikum Wels-Grieskirchen GmbH Austria · Wels, Austria
  • Landesklinikum Wiener Neustadt · Wiener Neustadt, Austria
  • CHU HELORA - Hopital de Jolimont · Haine-Saint-Paul, Belgium
  • Universitair Ziekenhuis Leuven · Leuven, Belgium
  • Centre Hospitalier Chretien - Clinique MontLegia · Liège, Belgium
  • Institut Sainte Catherine · Avignon, France
  • Centre Hospitalier Universitaire Nantes-Hotel Dieu · Nantes, France
  • Hopital Saint-Louis · Paris, France
  • CHU Bordeaux Hopital Haut Leveque · Pessac, France
  • LMU Klinikum - Campus Großhadern · München, Germany
  • Medizinische Hochschule Hannover (MHH) · Hanover, Germany
  • Klinikum St. Marien Amberg · Amberg, Germany
  • …and 34 more on the registry record
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Active, not recruiting
    17 sites added, 64 sites removed; no longer in Austria
    Show 17 added (14 United States, 2 Italy, 1 United Kingdom)
    • Mount Sinai Braman Comprehensive Cancer Center · Miami Beach, United States
    • Minnesota Oncology & Ridgeview Cancer & Infusion Center · Waconia, United States
    • Memorial Sloan Kettering Cancer Center - Main Campus · New York, United States
    • Texas Oncology - DFW · Arlington, United States
    • Texas Oncology - DFW · Arlington, United States
    • Texas Oncology - DFW · Bedford, United States
    • Texas Oncology - DFW · Dallas, United States
    • Texas Oncology - DFW · Dallas, United States
    • Texas Oncology - DFW · Dallas, United States
    • Texas Oncology - DFW · Dallas, United States
    • Texas Oncology - DFW · Fort Worth, United States
    • Texas Oncology - DFW · Grapevine, United States
    • Texas Oncology - DFW · Plano, United States
    • Texas Oncology - DFW · Plano, United States
    • IRCCS Azienda Ospedaliera Metropolitana (IRCCS AOM) · Genova, Italy
    • Azienda Ospedaliera Universitaria Luigi Vanvitelli · Naples, Italy
    • Cambridge University Hospitals NHS Foundation Trust, Oncology Centre · Cambridge, United Kingdom
    Show 64 removed
    • University of Southern California · Los Angeles, United States
    • Mount Sinai Comprehensive Cancer Center · Miami Beach, United States
    • Minnesota Oncology Hematology, PA · Fridley, United States
    • Minnesota Oncology Hematology, PA · Minneapolis, United States
    • Memorial Solan Kettering Cancer Center- Main Campus · New York, United States
    • Providence Cancer Institute Newberg Clinic · Newberg, United States
    • Providence Cancer Institute Willamette Falls Clinic · Oregon City, United States
    • Providence Portland Medical Center-Westside · Portland, United States
    • Providence St. Vincent Medical Center- Investigational Drug Services · Portland, United States
    • UPMC Hillman Cancer Center - Washington · Washington, United States
    • US Oncology Investigational Product Center (IPC) · Irving, United States
    • US Oncology Investigational Products Center (IPC) · Irving, United States
    • Providence Regional Cancer Partnership · Everett, United States
    • Providence Regional Medical Center Everett · Everett, United States
    • Princess Alexandra Hospital · Woolloongabba, Australia
    • Klinikum Wels-Grieskirchen GmbH Austria · Wels, Austria
    • Uniklinikum Salzburg, Landeskrankenhaus · Salzburg, Austria
    • AKH - Medizinische Universitat Wien · Vienna, Austria
    • Klinikum Wels-Grieskirchen GmbH Austria · Wels, Austria
    • Landesklinikum Wiener Neustadt · Wiener Neustadt, Austria
    • CHU HELORA - Hopital de Jolimont · Haine-Saint-Paul, Belgium
    • Universitair Ziekenhuis Leuven · Leuven, Belgium
    • Centre Hospitalier Chretien - Clinique MontLegia · Liège, Belgium
    • Institut Sainte Catherine · Avignon, France
    • Centre Hospitalier Universitaire Nantes-Hotel Dieu · Nantes, France
    • Hopital Saint-Louis · Paris, France
    • CHU Bordeaux Hopital Haut Leveque · Pessac, France
    • LMU Klinikum - Campus Großhadern · München, Germany
    • Medizinische Hochschule Hannover (MHH) · Hanover, Germany
    • Klinikum St. Marien Amberg · Amberg, Germany
    • …and 34 more on the registry record
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05253651
Responsible party
Sponsor
First posted
Feb 24, 2022
Start date
Oct 24, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Jul 3, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tucatinib · Trastuzumab

Start the discussion